Peter Mac researchers have discovered a powerful new drug combination that could offer hope to children and adults with ...

Relapsed/refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) are aggressive blood cancers that often resist standard therapy. Patients with these lymphomas may require stem cell ...

In 2016, the health ministry prohibited the sale of 344 fixed-dose combination drugs.However, after the move was challenged in the Delhi High Court by drug manufacturers, only 14 drugs were banned ...

Gilead Sciences said a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women with a less common, but aggressive form of breast cancer.

The drugs rapamycin and trametinib given together as a combination can increase mice lifespan by up to 30 per cent, say researchers, including from the Max Planck Institute for Biology of Ageing.

We just cannot yet predict which drug by itself is best for which patient, so everyone gets the combination.” These results led the researchers to wonder just how 5-FU was working, if not by ...

Trodelvy, in combination with Merck’s immunotherapy Keytruda, lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to new results ...

A new combination of cancer medications appears to extend overall survival in patients with advanced bladder cancer more than the chemotherapies currently used as the standard of care.. The ...

This combination therapy would prevent more than 330,000 deaths a year worldwide among patients who have already suffered a heart attack, including almost 50,000 deaths in the U.S. alone ...